Andreas Kalcker has repeatedly cited patent applications and recognitions to legitimize chlorine dioxide solution (CDS) as a therapeutic intervention, particularly for conditions like sepsis, viral infections, and chronic diseases. While these claims form a cornerstone of his advocacy, they remain enmeshed in controversy due to a lack of peer-reviewed validation and regulatory approval.

Kalcker’s most referenced intellectual property achievement is a Swiss patent application (not an granted patent) for the use of chlorine dioxide in treating sepsis and infectious diseases. This application emphasizes CDS’s purported ability to modulate oxidative stress and immune response, citing in vitro studies where chlorine dioxide demonstrated antimicrobial effects at low concentrations (0.3–0.8 mg/L) . Notably, the application relies on mechanistic theories—such as CDS’s impact on oxidation-reduction potential (ORP) and zeta potential in red blood cells—to argue for improved oxygen delivery and pathogen elimination . However, the patent has not progressed to granted status, and its claims lack clinical trial substantiation.

Beyond sepsis, Kalcker asserts global recognition from alternative health organizations. The Coalition Mundial por la Salud y la Vida (COMUSAV), a group of healthcare workers promoting CDS, frequently references his protocols, though no major medical institution endorses them . Additionally, Kalcker’s books, such as The Essentials: CDS Protocol Guide, frame his methods as "revolutionary," yet they are self-published and absent from mainstream medical literature .

Critics, including the FDA and WHO, dismiss these claims as dangerous misinformation. Kalcker’s alleged "patents" are viewed as marketing tools rather than scientific validations, especially amid ongoing legal battles—such as his 2021 charges in Argentina for illegal medical practice following a child’s death from CDS ingestion .

While Kalcker’s followers see patents as proof of innovation, the scientific community demands rigorous evidence. Until controlled trials confirm CDS’s safety and efficacy, these recognitions remain speculative—a testament to the divide between alternative therapeutic enthusiasm and evidence-based medicine.

Andreas Kalcker has repeatedly cited patent applications and recognitions to legitimize chlorine dioxide solution (CDS) as a therapeutic intervention, particularly for conditions like sepsis, viral infections, and chronic diseases. While these claims form a cornerstone of his advocacy, they remain enmeshed in controversy due to a lack of peer-reviewed validation and regulatory approval.

Kalcker’s most referenced intellectual property achievement is a Swiss patent application (not an granted patent) for the use of chlorine dioxide in treating sepsis and infectious diseases. This application emphasizes CDS’s purported ability to modulate oxidative stress and immune response, citing in vitro studies where chlorine dioxide demonstrated antimicrobial effects at low concentrations (0.3–0.8 mg/L) . Notably, the application relies on mechanistic theories—such as CDS’s impact on oxidation-reduction potential (ORP) and zeta potential in red blood cells—to argue for improved oxygen delivery and pathogen elimination . However, the patent has not progressed to granted status, and its claims lack clinical trial substantiation.

Beyond sepsis, Kalcker asserts global recognition from alternative health organizations. The Coalition Mundial por la Salud y la Vida (COMUSAV), a group of healthcare workers promoting CDS, frequently references his protocols, though no major medical institution endorses them . Additionally, Kalcker’s books, such as The Essentials: CDS Protocol Guide, frame his methods as "revolutionary," yet they are self-published and absent from mainstream medical literature .

Critics, including the FDA and WHO, dismiss these claims as dangerous misinformation. Kalcker’s alleged "patents" are viewed as marketing tools rather than scientific validations, especially amid ongoing legal battles—such as his 2021 charges in Argentina for illegal medical practice following a child’s death from CDS ingestion .

While Kalcker’s followers see patents as proof of innovation, the scientific community demands rigorous evidence. Until controlled trials confirm CDS’s safety and efficacy, these recognitions remain speculative—a testament to the divide between alternative therapeutic enthusiasm and evidence-based medicine.